Announcements Trials
Browse Landscape

Phase

Phase NA 52Phase 2 4Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1

Conditions

Pharyngeal Neoplasms 1Neoplasms 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Resistance Training × Clear all
NCT01332682 2023-10-18

Resistance Training and Physical Functioning in Head and Neck Cancer Patients

University of Alabama at Birmingham

Phase 1 Completed
18 enrolled
Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Pharyngeal Neoplasms

NCT00798200 2016-03-03

CanWell

McMaster University

Phase 1 Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡